Connexin 32 and luteolin play protective roles in nonalcoholic steatohepatitis development and its related hepatocarcinogenesis in rats

Carcinogenesis

Volumn 36, Issue 12, 2015, Pages 1539-1549

  Sagawa, Hiroyuki ^a   Naiki Ito, Aya ^a   Kato, Hiroyuki ^a   Naiki, Taku ^a   Yamashita, Yoriko ^a   Suzuki, Shugo ^a   Sato, Shinya ^a   Shiomi, Kosuke ^a   Kato, Akihisa ^a   Kuno, Toshiya ^a   Matsuo, Yoichi ^a   Kimura, Masahiro ^a   Takeyama, Hiromitsu ^a   Takahashi, Satoru ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CONNEXIN 26; CONNEXIN 32; CYTOKINE; GAP JUNCTION PROTEIN; LUTEOLIN;

ANIMAL; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; COMPLICATION; DISEASE COURSE; LIVER; LIVER CELL; LIVER NEOPLASMS, EXPERIMENTAL; MALE; METABOLISM; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOLOGY; PHYSIOLOGY; PRECANCER; PROTECTION; TRANSGENIC RAT; TUMOR CELL LINE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CONNEXINS; CYTOKINES; DISEASE PROGRESSION; HEPATOCYTES; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; LUTEOLIN; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; PRECANCEROUS CONDITIONS; PROTECTIVE FACTORS; RATS, TRANSGENIC;

EID: 84949799095     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgv143     Document Type: Article

References (50)

1. Bedogni, G. et al. (2005) Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology, 42, 44-52.
2. Browning, J.D. et al. (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology, 40, 1387-1395.
3. Anstee, Q.M. et al. (2013) Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol., 10, 330-344.
4. El-Serag, H.B. et al. (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132, 2557-2576.
5. Marchesini, G. et al. (2001) Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes, 50, 1844-1850.
6. Tilg, H. et al. (2010) Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology, 52, 1836-1846.
7. Tosello-Trampont, A.C. et al. (2012) Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-a production. J. Biol. Chem., 287, 40161-40172.
8. Shima, T. et al. (2015) Influence of lifestyle-related diseases and age on the development and progression of non-alcoholic fatty liver disease. Hepatol. Res., 45, 548-559.
9. Timchenko, N.A. (2009) Aging and liver regeneration. Trends Endocrinol. Metab., 20, 171-176.
10. Loewenstein, W.R. (1981) Junctional intercellular communication: the cell-to-cell membrane channel. Physiol. Rev., 61, 829-913.
11. Asamoto, M. et al. (2004) Connexin 32 dominant-negative mutant transgenic rats are resistant to hepatic damage by chemicals. Hepatology, 40, 205-210.
12. Hokaiwado, N. et al. (2005) Transgenic disruption of gap junctional intercellular communication enhances early but not late stage hepatocarcinogenesis in the rat. Toxicol. Pathol., 33, 695-701.
13. Krutovskikh, V.A. et al. (1991) Sequential changes of gap-junctional intercellular communications during multistage rat liver carcinogenesis: direct measurement of communication in vivo. Carcinogenesis, 12, 1701-1706.
14. Nakashima, Y. et al. (2004) Expression of gap junction protein connexin32 in chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. J. Gastroenterol., 39, 763-768.
15. Naiki-Ito, A. et al. (2012) Age-dependent carcinogenic susceptibility in rat liver is related to potential of gap junctional intercellular communication. Toxicol. Pathol., 40, 715-721.
16. Beecher, G.R. (2003) Overview of dietary flavonoids: nomenclature, occurrence and intake. J. Nutr., 133, 3248S-3254S.
17. Ross, J.A. et al. (2002) Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu. Rev. Nutr., 22, 19-34.
18. Ren, W. et al. (2003) Flavonoids: promising anticancer agents. Med. Res. Rev., 23, 519-534.
19. Gómez-Zorita, S. et al. (2012) Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br. J. Nutr., 107, 202-210.
20. Marcolin, E. et al. (2013) Quercetin decreases liver damage in mice with non-alcoholic steatohepatitis. Basic Clin. Pharmacol. Toxicol., 112, 385-391.
21. López-Lázaro, M. (2009) Distribution and biological activities of the flavonoid luteolin. Mini Rev. Med. Chem., 9, 31-59.
22. Kleiner, D.E. et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 41, 1313-1321.
23. Hokaiwado, N. et al. (2007) Both early and late stages of hepatocarcinogenesis are enhanced in Cx32 dominant negative mutant transgenic rats with disrupted gap junctional intercellular communication. J. Membr. Biol., 218, 101-106.
24. Ogawa, K. et al. (2001) Establishment of rat hepatocellular carcinoma cell lines with differing metastatic potential in nude mice. Int. J. Cancer, 91, 797-802.
25. Yamashita, Y. et al. (2006) Immortalization of Epstein-Barr virus-negative human B lymphocytes with minimal chromosomal instability. Pathol. Int., 56, 659-667.
26. Tanaka, N. et al. (2012) Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology, 56, 118-129.
27. Yamaguchi, K. et al. (2008) Diacylglycerol acyltranferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis. Hepatology, 47, 625-635.
28. Temme, A. et al. (1997) High incidence of spontaneous and chemically induced liver tumors in mice deficient for connexin32. Curr. Biol., 7, 713-716.
29. Duffy, H.S. et al. (2007) The gap junction protein connexin32 interacts with the Src homology 3/hook domain of discs large homolog 1. J. Biol. Chem., 282, 9789-9796.
30. Mones, S. et al. (2012) Connexin 32 is involved in mitosis. Glia, 60, 457-464.
31. Naiki-Ito, A. et al. (2010) Gap junction dysfunction reduces acetaminophen hepatotoxicity with impact on apoptotic signaling and connexin 43 protein induction in rat. Toxicol. Pathol., 38, 280-286.
32. Tang, M. et al. (2009) Induction of apoptosis in the LNCaP human prostate carcinoma cell line and prostate adenocarcinomas of SV40T antigen transgenic rats by the Bowman-Birk inhibitor. Pathol. Int., 59, 790-796.
33. Tuorkey, M.J. (2015) Molecular targets of luteolin in cancer. Eur. J. Cancer Prev.
34. Li, J. et al. (2015) Antifibrotic effects of luteolin on hepatic stellate cells and liver fibrosis by targeting AKT/mTOR/p70S6K and TGFß/Smad signalling pathways. Liver Int., 35, 1222-1233.
35. Domitrovic, R. et al. (2009) Liver fibrosis in mice induced by carbon tetrachloride and its reversion by luteolin. Toxicol. Appl. Pharmacol., 241, 311-321.
36. Henao-Mejia, J. et al. (2012) Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature, 482, 179-185.
37. Martinon, F. et al. (2004) Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell, 117, 561-574.
38. Yu, H.B. et al. (2008) The caspase-1 inflammasome: a pilot of innate immune responses. Cell Host Microbe, 4, 198-208.
39. Videla, L.A. et al. (2009) Liver NF-kappaB and AP-1 DNA binding in obese patients. Obesity (Silver Spring), 17, 973-979.
40. Dela Peña, A. et al. (2005) NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology, 129, 1663-1674.
41. Park, H.J. et al. (2012) Green tea extract suppresses NF?B activation and inflammatory responses in diet-induced obese rats with nonalcoholic steatohepatitis. J. Nutr., 142, 57-63.
42. Yang, Q.S. et al. (2002) Cloning and expression pattern of a spermatogenesis- related gene, BEX1, mapped to chromosome Xq22. Biochem. Genet., 40, 1-12.
43. Foltz, G. et al. (2006) Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma. Cancer Res., 66, 6665-6674.
44. Lee, C.H. et al. (2013) Epigenetic regulation of the X-linked tumour suppressors BEX1 and LDOC1 in oral squamous cell carcinoma. J. Pathol., 230, 298-309.
45. Inokuchi, S. et al. (2010) Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis. Proc. Natl Acad. Sci. USA, 107, 844-849.
46. Uehara, T. et al. (2013) Molecular mechanisms of fibrosis-associated promotion of liver carcinogenesis. Toxicol. Sci., 132, 53-63.
47. Jiang, J.H. et al. (2013) An X-chromosomal association study identifies a susceptibility locus at Xq22.1 for hepatitis B virus-related hepatocellular carcinoma. Clin. Res. Hepatol. Gastroenterol., 37, 586-595.
48. Attoub, S. et al. (2011) Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells. Eur. J. Pharmacol., 651, 18-25.
49. Vilar, M. et al. (2006) Bex1, a novel interactor of the p75 neurotrophin receptor, links neurotrophin signaling to the cell cycle. EMBO J., 25, 1219-1230.
50. Ding, K. et al. (2009) Inhibition of apoptosis by downregulation of hBex1, a novel mechanism, contributes to the chemoresistance of Bcr/ Abl+ leukemic cells. Carcinogenesis, 30, 35-42.